Appointments at Morphotek and Qualitest and resignations at Sigma-Aldrich and GenVec – People on the move

By Nick Taylor

- Last updated on GMT

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Morphotek and Qualitest and resignations at Sigma-Aldrich and GenVec.

Morphotek ​has appointed Joye Bramble ​as vice president (VP), pilot plant operations, giving her responsibility for management and operation of its new biologics production facility. Bramble most recently worked at Merck Research Labs, a company she joined in 1990.

David Julien ​is to retire as president, global supply chain at Sigma-Aldrich​. Joseph Porwoll​ has been promoted to VP, global supply chain to takeover the responsibilities held by Julien.

Qualitest Pharmaceuticals​ has named Robert Mills ​as its president. Mills has more than 30 years of pharma experience which he gained working at Columbia Laboratories, Watson Pharmaceuticals, Schein Pharmaceuticals and Alpharma.

Mark Thornton​ has resigned from the position of SVP, product development at GenVec​. Thornton worked at GenVec for three years but has now accepted position at another company.

Strativa Pharmaceuticals ​has promoted Melissa Masterson​ to the position of VP, managed markets. Masterson joined Strativa in 2006 having spent the previous 11 years at Forest Pharmaceuticals.

Mark Smith ​has resigned as chief financial officer of Sigma Pharmaceuticals​ a month after Elmo de Alwis, the then CEO, stepped down. John Stocker​, chairman of Sigma, also intends to retire. Last week, South Africa-based Aspen offered A$1.5m ($1.2m) to acquire Sigma.

Oramed Pharmaceuticals ​has appointed Michael Berelowitz​ to its board of directors. Berelowitz is currently SVP and head of clinical development and medical affairs in the speciality care business unit at Pfizer. He has worked at Pfizer since 1996.

Related topics Markets & regulatory news

Related news

Show more

Follow us

Products

View more

Webinars